| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| ln Vitro |
BRP (50-100 μg/mL; 0-24 h) TFA can induce potent, sustained and non-desensitized Fos expression in NS-1 rat neurons, with an EC50 value of 33.7 μM at 24 h and 37 μM at 1 h [1]. BRP (50-100 μg/mL; 0-24 h) TFA can induce potent, sustained and non-desensitized Fos expression in mouse Neuro2a neurons, with an EC50 value of 33 μM at 24 h and 27 μM at 1 h, and activate the CREB and ERK1/2 signaling pathways [1]. BRP (100 μg/mL; 0-40 min) TFA can increase the cAMP level in mouse Neuro2a neurons [1]. BRP (100 μg/mL; 15 min) TFA can induce phosphorylation of CREB at Ser133 site, ERK1/2 phosphorylation and PKA substrate phosphorylation in Neuro2a neurons[1].
|
|---|---|
| ln Vivo |
BRP (0.5-20 mg/kg; intraperitoneal, intranasal, intraventricular; single-dose) TFA can inhibit food intake in lean male and female C57BL/6J mice in a dose-dependent manner via intraperitoneal, intranasal, or intraventricular injection routes [1]. BRP (5 mg/kg; intraperitoneal; once daily; for 14 days) TFA can reverse diet-induced obesity in male C57BL/6J mice and improve glucose homeostasis by reducing food intake and fat intake [1]. BRP (2 mg/kg; intramuscular; single-dose) TFA can inhibit feeding behavior in male Yucatan miniature pigs without inducing anxiety-like behavior [1].
|
| Animal Protocol |
Animal/Disease Models:C57BL/6J (8-week-old males; 8-week-old females) [1]
Doses: 0.5-20 mg/kg (intraperitoneal injection, single dose); 10 mg/kg (intravenous injection, single dose); 0.5 mg/kg (intraventricular injection, single dose) Route of Administration: Intraperitoneal injection (single dose); Intravenous injection (single dose); Intraventricular injection (single dose, injected into the lateral ventricle within approximately 30 seconds) Experimental Results: Intraperitoneal injection of 5 mg/kg potently and rapidly suppressed food intake in lean male mice for up to 3 hours. Intraperitoneal injection of 20 mg/kg almost completely suppressed food intake in lean male mice for up to 3 hours. Intraperitoneal injection of 0.5 mg/kg did not reduce food intake in lean male mice. Intraperitoneal injection of 5 mg/kg suppressed food intake in lean female mice within 3 hours. Intraperitoneal injection of 10 mg/kg suppressed food intake in lean male mice within 3 hours. Intravenous injection of 10 mg/kg suppressed food intake in lean male mice within 3 hours. Intraventricular injection of 0.5 mg/kg suppressed food intake in lean male mice within 3 hours. Animal/Disease Models:C57BL/6J (6-week diet-induced obese male mice) [1] Doses: 1-5 mg/kg Route of Administration: Intraperitoneal injection (once daily; 14 days) Experimental Results: Reduced cumulative food intake and body weight. Improved glucose tolerance and insulin tolerance. Reduced the mass of inguinal white adipose tissue, brown adipose tissue and liver, reduced the volume of adipocytes in inguinal white adipose tissue, reduced ectopic hepatic lipid deposition, and reduced fat mass without affecting lean body mass. |
| References |
| Molecular Formula |
C68H117N25O14S.XC2HF3O2
|
|---|---|
| Molecular Weight |
1540.88 (free base)
|
| Related CAS # |
BRP
|
| Sequence |
Thr-His-Arg-Ile-Leu-Arg-Arg-Leu-Phe-Asn-Leu-Cys-NH2THRILRRLFNLC-NH2
|
| SequenceShortening |
THRILRRLFNLC-NH2
|
| Appearance |
Solid
|
| Synonyms |
BRINP2-related peptide TFA
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: 请将本产品存放在密封保护的环境中，避免受潮。 |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
